CA2668286C — Bruton's tyrosine kinase activity probe and method of using
Assigned to Pharmacyclics LLC · Expires 2014-09-16 · 12y expired
What this patent protects
Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use. The invention relates to a Btk activity probe comprising a Btk inhibitor moiety, a reporter moiety, and a linker…
USPTO Abstract
Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use. The invention relates to a Btk activity probe comprising a Btk inhibitor moiety, a reporter moiety, and a linker moiety that links the inhibitor moiety to the reporter moiety. Specifically described are a Btk inhibitor moiety which covalently bonds to a cysteine residue of a Btk enzyme, a fluorophore and a linker moiety that links the inhibitor moiety to the fluorophore. In an embodiment, the Btk activity probe is: (see compound 3)
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.